Repligen Corporation Common Stock vs ZIM Integrated Shipping Services Ltd — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while ZIM Integrated Shipping Services Ltd trades at $29.84 (market cap $3.67B). The key difference: Repligen Corporation Common Stock is far larger — about 3× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and ZIM Integrated Shipping Services Ltd for 23 Days on average.
| RGEN | ZIM | |
|---|---|---|
Market Cap | $11.14B | $3.67B |
Volume | 1,259,263 | 1,172,596 |
Sector | Health | Industrials |
52-Week High | $194.57 | $30.90 |
52-Week Low | $102.87 | $13.32 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.02B | $7.34B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
ZIM trades at $30.43, down 1.52% on the day, with a bullish technical signal from moving averages. The stock is near its 52-week high of $30.96, reflecting strong momentum. Fundamentally, Q2 2026 earnings of $0.53 per share significantly beat expectations, driven by a 9% revenue increase to $1.8 billion, though full-year 2026 guidance indicates margin pressure. The pending $35 per share acquisition offer from Hapag-Lloyd, subject to Israeli government approval, creates a key near-term catalyst.
The investment case balances potential upside from the acquisition against operational risks. If approved, the deal offers immediate premium; if rejected, ZIM's standalone value hinges on sustaining high transpacific freight rates. Analyst sentiment is cautious with no buy ratings, highlighting execution and geopolitical risks. The stock presents a speculative opportunity with binary outcomes centered on the merger decision.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →